Biotech RadarJobs updated

COMPANY

Altimmune

HQ: Gaithersburg, MD source · altimmune.com ↗

Clinical Phase 3

Altimmune is a late-stage clinical biopharmaceutical company focused on serious liver disease. From company website Source · Oct 12, 2026

Keywords: Influenza Non-Alcoholic Fatty Liver Disease Metabolic Dysfunction-Associated Steatohepatitis Alcohol-associated Liver Disease Alcohol Use Disorder Non-Alcoholic Steatohepatitis Chronic Hepatitis B NASH - Nonalcoholic Steatohepatitis Type 2 Diabetes Obesity Nonalcoholic Steatohepatitis Influenza A Subtype H5N1 Infection Hepatitis B Obesity/Overweight Coronavirus Infection Pemvidutide ALT-801 NasoVAX HepTcell NasoShield Subjects were administered NasoVAX high dose

Location: Gaithersburg, MD · source · Oct 14, 2026

Profile checked Oct 10, 2026

$300.0MRaised (2 yrs)20Trials (company is sponsor)

Timeline

  1. Trial start 3: Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH source ↗
  2. Raise Follow-on offering: $225M (total, as published), announced Apr 27, 2026. Source: company release on GlobeNewswire. source ↗
  3. Raise Follow-on offering — Registered direct: $75M (total, as published), announced Jan 29, 2026. Source: company release on GlobeNewswire. source ↗
  4. Trial start Phase 2: RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) source ↗
  5. Trial start 2: RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight source ↗
  6. Debt Debt financing: $100M (up to, as announced), announced May 13, 2025. Source: company release on GlobeNewswire. source ↗
  7. Trial start Phase 2: IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) source ↗
  8. Trial start Phase 2: Efficacy and Safety of ALT-801 in the Treatment of Obesity source ↗
  9. Trial start Phase 1: Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD) source ↗
  10. Trial start Phase 1: ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM) source ↗
  11. Trial start Phase 1: ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD) source ↗
  12. Trial start Phase 1: Pemvidutide (ALT-801) DDI Study in Healthy Volunteers source ↗
  13. Trial start Phase 1: Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study) source ↗
  14. Trial start Phase 2: HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) source ↗
  15. Trial start Phase 1: ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability source ↗
  16. Trial start Phase 2: NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19) source ↗
  17. Trial start Phase 1: NasoShield in Healthy Adults to Study Safety and Immunogenicity source ↗
  18. Trial start —: Study of the Safety and Immunogenicity of NasoVAX Extension source ↗
  19. Trial start Phase 1: NasoShield Study of Safety and Immunogenicity source ↗
  20. Trial start Phase 2: Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX source ↗
  21. Trial start Phase 4: Immune Response Following Seasonal Influenza Vaccination source ↗
  22. Trial start I: Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B source ↗
  23. Trial start Phase 1: Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine. source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $300.0M · Debt: $100.0M. Last 2 years.

Clinical trials (lead sponsor) 20

RecordTitlePhaseStatusStartPrimary completion
NCT07795164Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH3RecruitingJul 30, 20262028-12 (estimated)
NCT07009860RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)Phase 2Active, not recruitingJun 16, 2025Sep 30, 2027 (estimated)
NCT06987513RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight2CompletedMay 15, 2025Jul 30, 2026 (actual)
NCT05989711IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)Phase 2CompletedJul 27, 2023Nov 25, 2025 (actual)
NCT04684914HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)Phase 2TerminatedDec 26, 2020Mar 27, 2024 (actual)
NCT03352466NasoShield Study of Safety and ImmunogenicityPhase 1CompletedJan 18, 2018May 13, 2019 (actual)
NCT04972396Pemvidutide (ALT-801) DDI Study in Healthy VolunteersPhase 1CompletedSep 15, 2021May 15, 2022 (actual)
NCT04415749NasoShield in Healthy Adults to Study Safety and ImmunogenicityPhase 1CompletedJun 15, 2020Mar 15, 2021 (actual)
NCT05134662ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)Phase 1CompletedFeb 1, 2022Feb 3, 2023 (actual)
NCT04561245ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityPhase 1CompletedNov 10, 2020Oct 29, 2021 (actual)
NCT03760549Study of the Safety and Immunogenicity of NasoVAX ExtensionNot listedCompletedJan 21, 2019Feb 18, 2019 (actual)
NCT00755703Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.Phase 1Completed2008-102009-09 (actual)
NCT02496897Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis BICompleted2015-07Oct 13, 2017 (actual)
NCT03232567Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAXPhase 2CompletedSep 18, 2017Mar 7, 2018 (actual)
NCT05295875Efficacy and Safety of ALT-801 in the Treatment of ObesityPhase 2CompletedMar 31, 2022Sep 28, 2023 (actual)
NCT04679909Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)Phase 1CompletedFeb 25, 2021Dec 1, 2021 (actual)
NCT05006885ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)Phase 1CompletedSep 30, 2021Aug 17, 2022 (actual)
NCT05292911Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)Phase 1CompletedMar 9, 2022Oct 31, 2022 (actual)
NCT04442230NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)Phase 2TerminatedOct 10, 2020Feb 15, 2021 (actual)
NCT03163342Immune Response Following Seasonal Influenza VaccinationPhase 4CompletedMay 8, 2017Nov 21, 2017 (actual)
Feedback